Charles Payne asks Barbara Doran about the investment potential of Robinhood and Eli Lilly. Doran notes Robinhood (HOOD) is at a technical "moment of truth," while Eli Lilly (LLY) has seen a recent pullback, making it an enticing opportunity despite its valuation. She highlights Eli Lilly's multi-year growth potential, expanding platform, and success in the GLP-1 market, along with its other diverse product lines in cardiovascular, sleep apnea, osteoporosis, and diabetes treatments.